Changes

This study focused on a different patient cohort than the Brazil study as these were people presenting to the hospital rather than people seeking treatment right after they were infected which means it is closer to the Mount Sanai study.  So what did they find?

This study focused on a different patient cohort than the Brazil study as these were people presenting to the hospital rather than people seeking treatment right after they were infected which means it is closer to the Mount Sanai study.  So what did they find?

{{We analysed first 220 medical records. 166 patients met the inclusion criteria. 48.8 % of patients not treated with HCQ died, 22% of those treated with hydroxychloroquine <nowiki>(p=0.002)</nowiki>. According to clinical picture at admission, hydroxychloroquine increased the mean cumulative survival in all groups from 1.4 to 1.8 times. This difference was statistically significant in the mild group. Conclusions: in a cohort of 166 patients from 18 to 85 years hospitalised with COVID-19, hydroxychloroquine treatment with 800mg added loading dose increased survival when patients were admitted in early stages of the disease. There was a non-statistically significant trend towards survival in all groups, which will have to be clarified in subsequent studies.<ref name =Spainstud/>}}

{{quotebox|We analysed first 220 medical records. 166 patients met the inclusion criteria. 48.8 % of patients not treated with HCQ died, 22% of those treated with hydroxychloroquine <nowiki>(p=0.002)</nowiki>. According to clinical picture at admission, hydroxychloroquine increased the mean cumulative survival in all groups from 1.4 to 1.8 times. This difference was statistically significant in the mild group. Conclusions: in a cohort of 166 patients from 18 to 85 years hospitalised with COVID-19, hydroxychloroquine treatment with 800mg added loading dose increased survival when patients were admitted in early stages of the disease. There was a non-statistically significant trend towards survival in all groups, which will have to be clarified in subsequent studies.<ref name =Spainstud/>}}

P=0.002 is another ''highly'' significant result with potentially life saving implications that was in a preprint after the VA study but before Surgisphere.  The main disadvantage of this study was that it was small... 166 patients is not a high number.  

P=0.002 is another ''highly'' significant result with potentially life saving implications that was in a preprint after the VA study but before Surgisphere.  The main disadvantage of this study was that it was small... 166 patients is not a high number.